BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14:933-942. [PMID: 23932548 DOI: 10.1016/s1470-2045(13)70335-8] [Cited by in Crossref: 296] [Cited by in F6Publishing: 264] [Article Influence: 32.9] [Reference Citation Analysis]
Number Citing Articles
1 Noda M, Inaji M, Karakama J, Arai Y, Kuroha M, Tamura K, Tanaka Y, Maehara T. Ischemic Stroke with Multiple Cerebral Artery Stenosis in a Patient with an Anaplastic Astrocytoma during Bevacizumab Treatment: A Case Report. NMC Case Report Journal 2022;9:13-7. [DOI: 10.2176/jns-nmc.2021-0297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu Q, Guan C, Liu C, Li H, Wu J, Sun C. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy. Biomedicine & Pharmacotherapy 2022;156:113861. [DOI: 10.1016/j.biopha.2022.113861] [Reference Citation Analysis]
3 Agostinetto E, Gligorov J, Piccart M. Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol 2022. [PMID: 36253451 DOI: 10.1038/s41571-022-00687-1] [Reference Citation Analysis]
4 Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J Exp Clin Cancer Res 2022;41:265. [DOI: 10.1186/s13046-022-02476-1] [Reference Citation Analysis]
5 Pinilla K, Drewett LM, Lucey R, Abraham JE. Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. Front Oncol 2022;12:866889. [DOI: 10.3389/fonc.2022.866889] [Reference Citation Analysis]
6 Zhao X, Zhang T, Yan Y, Liu F, Li C, Fan J, Pan Y, Li X, Wang Y. Notch signaling regulates vessel structure and function via Hspg2. Gene 2022;826:146439. [PMID: 35339643 DOI: 10.1016/j.gene.2022.146439] [Reference Citation Analysis]
7 Rodriguez GV, Juvera Avalos ER, Gonzalez C, Barba de la Rosa AP, De Leon-rodriguez A. Production and optimization of a vasostatin-30 and vasoinhibin fusion protein that inhibits tumor angiogenesis and dissemination of breast cancer cells in a zebrafish model. Process Biochemistry 2022. [DOI: 10.1016/j.procbio.2022.05.002] [Reference Citation Analysis]
8 Gupta RK, Roy AM, Gupta A, Takabe K, Dhakal A, Opyrchal M, Kalinski P, Gandhi S. Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era? Cancers (Basel) 2022;14:1856. [PMID: 35454764 DOI: 10.3390/cancers14081856] [Reference Citation Analysis]
9 Ayoub NM, Jaradat SK, Al-shami KM, Alkhalifa AE. Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Front Pharmacol 2022;13:838133. [DOI: 10.3389/fphar.2022.838133] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
10 van Rossum AGJ, Mandjes IAM, van Werkhoven E, van Tinteren H, van Leeuwen-Stok AE, Nederlof P, Portielje JEA, van Alphen RJ, Platte E, van den Broek D, Huitema A, Kok M, Linn SC, Oosterkamp HM. Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). Breast Care (Basel) 2021;16:598-606. [PMID: 35087363 DOI: 10.1159/000512200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Mir MA, Sofi S, Qayoom H. Targeting biologically specific molecules in triple negative breast cancer (TNBC). Combinational Therapy in Triple Negative Breast Cancer 2022. [DOI: 10.1016/b978-0-323-96136-3.00002-9] [Reference Citation Analysis]
12 Mir MA, Aisha S, Mehraj U. Current therapeutics and treatment options in TNBC. Combinational Therapy in Triple Negative Breast Cancer 2022. [DOI: 10.1016/b978-0-323-96136-3.00007-8] [Reference Citation Analysis]
13 Mir MA, Sofi S, Qayoom H. Conventional adjuvant chemotherapy in combination with surgery, radiotherapy, and other specific targets. Combinational Therapy in Triple Negative Breast Cancer 2022. [DOI: 10.1016/b978-0-323-96136-3.00008-x] [Reference Citation Analysis]
14 Li Y, Zhan Z, Yin X, Fu S, Deng X. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer. Front Oncol 2021;11:731535. [PMID: 34778045 DOI: 10.3389/fonc.2021.731535] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
15 Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X, Xu Q. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Front Oncol 2021;11:683502. [PMID: 34692475 DOI: 10.3389/fonc.2021.683502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
16 Shiga T, Im J, Kikuchi N, Arakawa Y. The Effective Use of Digoxin in a Patient with Metastatic Breast Cancer and Anthracycline-induced Cardiomyopathy. Intern Med 2021;60:2819-23. [PMID: 33746165 DOI: 10.2169/internalmedicine.6787-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kubota S, Hara H, Hiroi Y. Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment. Glob Health Med 2021;3:214-25. [PMID: 34532602 DOI: 10.35772/ghm.2021.01024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, Ni C, Chen Z. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res 2021;9:59. [PMID: 34294146 DOI: 10.1186/s40364-021-00312-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
19 Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol Med 2021;13:e08253. [PMID: 34125494 DOI: 10.15252/emmm.201708253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
20 Gandhi S, Oshi M, Murthy V, Repasky EA, Takabe K. Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment. Cancers (Basel) 2021;13:2559. [PMID: 34071012 DOI: 10.3390/cancers13112559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
21 Xiao J, Rahbar H, Hippe DS, Rendi MH, Parker EU, Shekar N, Hirano M, Cheung KJ, Partridge SC. Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis. NPJ Breast Cancer 2021;7:42. [PMID: 33863924 DOI: 10.1038/s41523-021-00247-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
22 Díaz-Gavela AA, Figueiras-Graillet L, Luis ÁM, Salas Segura J, Ciérvide R, Del Cerro Peñalver E, Couñago F, Arenas M, López-Fernández T. Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies. Cancers (Basel) 2021;13:1712. [PMID: 33916644 DOI: 10.3390/cancers13071712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Chu T, Lu J, Bi M, Zhang H, Zhuang W, Yu Y, Shi J, Chen Z, Zhang X, Guo Q, Liu Q, Wu H, Fang J, Hu Y, Wang X, Han C, Li K, Han B. Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer Biol Med 2021:j. [PMID: 33710815 DOI: 10.20892/j.issn.2095-3941.2020.0212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
24 Mezi S, Botticelli A, Pomati G, Cerbelli B, Scagnoli S, Amirhassankhani S, d'Amati G, Marchetti P. Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:1080. [PMID: 33802438 DOI: 10.3390/cancers13051080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Mouron S, Bueno MJ, Muñoz M, Quintela-Fandino M. Monitoring vascular normalization: new opportunities for mitochondrial inhibitors in breast cancer. Oncoscience 2021;8:1-13. [PMID: 33869665 DOI: 10.18632/oncoscience.523] [Reference Citation Analysis]
26 Guha R, Yue B, Dong J, Banerjee A, Serrero G. Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration. Breast Cancer Res Treat 2021;186:637-53. [PMID: 33616772 DOI: 10.1007/s10549-021-06120-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
27 He B, Ganss R. Modulation of the Vascular-Immune Environment in Metastatic Cancer. Cancers (Basel) 2021;13:810. [PMID: 33671981 DOI: 10.3390/cancers13040810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
28 Xie W, Zhao H, Wang F, Wang Y, He Y, Wang T, Zhang K, Yang H, Zhou Z, Shi H, Wang J, Huang G. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res 2021;40:30. [PMID: 33436039 DOI: 10.1186/s13046-020-01800-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
29 Sabatier R, Pierga JY, Curé H, Abulnaja R, Lambaudie E, Bidard FC, Extra JM, Sfumato P, Gonçalves A. Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers (Basel) 2021;13:E140. [PMID: 33466225 DOI: 10.3390/cancers13010140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Layoun ME, Ferencik M. Cardiovascular Complications. Blood and Marrow Transplant Handbook 2021. [DOI: 10.1007/978-3-030-53626-8_34] [Reference Citation Analysis]
31 Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. Breast Cancer (Auckl) 2020;14:1178223420980377. [PMID: 33402827 DOI: 10.1177/1178223420980377] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
32 Wang H, Wang X, Zhang Y, Cheng R, Yuan J, Zhong Z. Systemic Delivery of NAC-1 siRNA by Neuropilin-Targeted Polymersomes Sensitizes Antiangiogenic Therapy of Metastatic Triple-Negative Breast Cancer. Biomacromolecules 2020;21:5119-27. [PMID: 33174734 DOI: 10.1021/acs.biomac.0c01253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
33 Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, Vallejo-Lecuona F, de la Cruz-Montoya A, Porras Reyes FI, Pérez-Sánchez VM, Maldonado-Martínez HA, Robles-Estrada M, Bargalló-Rocha E, Cabrera-Galeana P, Ramos-Ramírez M, Chirino YI, Alonso Herrera L, Terrazas LI, Oliver J, Frecha C, Perdomo S, Vaca-Paniagua F. Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic. Genes (Basel) 2020;11:E1367. [PMID: 33227964 DOI: 10.3390/genes11111367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Yang X, Li G, Yang T, Guan M, An N, Yang F, Dai Q, Zhong C, Luo C, Gao Y, Das S, Xing Y, Shang H. Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity. Oxid Med Cell Longev 2020;2020:4894625. [PMID: 33110473 DOI: 10.1155/2020/4894625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
35 Chainitikun S, Saleem S, Lim B, Valero V, Ueno NT. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res 2021;29:1-12. [PMID: 33842000 DOI: 10.1016/j.jare.2020.08.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
36 Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel) 2020;12:E2392. [PMID: 32846967 DOI: 10.3390/cancers12092392] [Cited by in Crossref: 86] [Cited by in F6Publishing: 87] [Article Influence: 43.0] [Reference Citation Analysis]
37 Wu SY, Wang H, Shao ZM, Jiang YZ. Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Sci China Life Sci 2021;64:372-88. [PMID: 32803712 DOI: 10.1007/s11427-020-1714-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
38 Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res 2021;31:178-86. [PMID: 32719455 DOI: 10.1038/s41422-020-0375-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 67] [Article Influence: 28.0] [Reference Citation Analysis]
39 Sabater-Molina M, Navarro-Peñalver M, Muñoz-Esparza C, Esteban-Gil Á, Santos-Mateo JJ, Gimeno JR. Genetic Factors Involved in Cardiomyopathies and in Cancer. J Clin Med 2020;9:E1702. [PMID: 32498335 DOI: 10.3390/jcm9061702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Rinnerthaler G, Gampenrieder SP, Hackl H, Steiner M, Monzo-Fuentes C, Melchardt T, Magnes T, Huemer F, Westphal T, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. J Clin Med 2020;9:E1663. [PMID: 32492882 DOI: 10.3390/jcm9061663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
41 Komorowski AS, MacKay HJ, Pezo RC. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. Cancer Med 2020;9:5035-50. [PMID: 32452660 DOI: 10.1002/cam4.3095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 28.0] [Reference Citation Analysis]
43 Park B, Sim SH, Lee KS, Kim HJ, Park IH. Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer. Cancer Sci 2020;111:2579-87. [PMID: 32378780 DOI: 10.1111/cas.14446] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
44 Avila MS, Siqueira SRR, Ferreira SMA, Bocchi EA. Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity. Methodist Debakey Cardiovasc J 2019;15:267-73. [PMID: 31988687 DOI: 10.14797/mdcj-15-4-267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
45 Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Goen AE, Kinlaw WB, Miller TW. AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells. Clin Cancer Res 2020;26:3707-19. [PMID: 32321715 DOI: 10.1158/1078-0432.CCR-20-0269] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
46 Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers (Basel) 2020;12:E916. [PMID: 32276534 DOI: 10.3390/cancers12040916] [Cited by in Crossref: 114] [Cited by in F6Publishing: 121] [Article Influence: 57.0] [Reference Citation Analysis]
47 Zhao S, Zuo WJ, Shao ZM, Jiang YZ. Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med 2020;8:499. [PMID: 32395543 DOI: 10.21037/atm.2020.03.194] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 17.0] [Reference Citation Analysis]
48 Hampsch RA, Wells JD, Traphagen NA, Mccleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Kinlaw WB, Miller TW. AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells.. [DOI: 10.1101/2020.01.21.914382] [Reference Citation Analysis]
49 Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, Sotiriou C. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol. 2018;29:895-902. [PMID: 29365031 DOI: 10.1093/annonc/mdy024] [Cited by in Crossref: 149] [Cited by in F6Publishing: 158] [Article Influence: 49.7] [Reference Citation Analysis]
50 Fitzpatrick A, Tutt A. Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. Ther Adv Med Oncol 2019;11:1758835919882581. [PMID: 31700549 DOI: 10.1177/1758835919882581] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
51 Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A, Massimiani G, Pelle F, Kayal R, Vizza E, Grassadonia A, Tomao S, Venuti A, Gamucci T, Marchetti P, Natoli C, Sanguineti G, Ciliberto G, Vici P. Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. J Cancer 2019;10:5903-14. [PMID: 31762800 DOI: 10.7150/jca.35109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
52 Nakhjavani M, Hardingham JE, Palethorpe HM, Price TJ, Townsend AR. Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. J Breast Cancer 2019;22:341-61. [PMID: 31598336 DOI: 10.4048/jbc.2019.22.e39] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
53 Clément-Zhao A, Tanguy ML, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Savignoni A, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation. PLoS One 2019;14:e0221816. [PMID: 31469859 DOI: 10.1371/journal.pone.0221816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
54 Gullo G, J Eustace A, Canonici A, M Collins D, Kennedy MJ, Grogan L, Breathhnach O, McCaffrey J, Keane M, Martin MJ, Gupta R, Leonard G, O'Connor M, Calvert PM, Donnellan P, Walshe J, McDermott E, Scott K, Hernando A, Parker I, W Murray D, C O'Farrell A, Maratha A, Dicker P, Rafferty M, Murphy V, O'Donovan N, M Gallagher W, Ky B, Tryfonopoulos D, Moulton B, T Byrne A, Crown J. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial. Ther Adv Med Oncol 2019;11:1758835919864236. [PMID: 31384312 DOI: 10.1177/1758835919864236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
55 Miller IS, Shiels LP, Conroy E, Connor K, Dicker P, Gallagher WM, Donovan NO, Kerbel RS, Crown J, Byrne AT. Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents. Sci Rep 2019;9:9204. [PMID: 31235775 DOI: 10.1038/s41598-019-45444-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Zhao Z, Li Y, Shukla R, Liu H, Jain A, Barve A, Cheng K. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer. Theranostics 2019;9:4508-24. [PMID: 31285776 DOI: 10.7150/thno.34314] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
57 Pandey G, Borcherding N, Kolb R, Kluz P, Li W, Sugg S, Zhang J, Lai DA, Zhang W. ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. Cancers (Basel) 2019;11:E718. [PMID: 31137681 DOI: 10.3390/cancers11050718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
58 Appell PG, Rüssel J, Schlitt A. Kardiotoxizität onkologischer Therapien (2): KHK, Vitien, Arrhythmien, Hypertonie und Thrombosen. Deutsches Ärzteblatt Online 2019. [DOI: 10.3238/perskardio.2019.04.12.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Roviello G, Generali D, Sobhani N. The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study. Transl Cancer Res 2019;8:S94-6. [PMID: 35117071 DOI: 10.21037/tcr.2018.10.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Colomer R, Saura C, Sánchez-Rovira P, Pascual T, Rubio IT, Burgués O, Marcos L, Rodríguez CA, Martín M, Lluch A. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Oncologist 2019;24:603-11. [PMID: 30710068 DOI: 10.1634/theoncologist.2018-0228] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
61 Nahleh Z, Botrus G, Dwivedi A, Jennings M, Nagy S, Tfayli A. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol 2019;10:357-65. [PMID: 30847174 DOI: 10.3892/mco.2019.1796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
62 Ozer L, Aydiner A. Adjuvant Systemic Chemotherapy for HER2-Negative Disease. Breast Disease 2019. [DOI: 10.1007/978-3-030-16792-9_8] [Reference Citation Analysis]
63 Liang X, Li H, Coussy F, Callens C, Lerebours F. An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress? Chin J Cancer Res 2019;31:586-600. [PMID: 31564802 DOI: 10.21147/j.issn.1000-9604.2019.04.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
64 Banys-paluchowski M, Fehm T, Müller V. The Value of Anti-angiogenics in Breast Cancer Therapy. Tumor Angiogenesis 2019. [DOI: 10.1007/978-3-319-33673-2_24] [Reference Citation Analysis]
65 Okutur K, Demir G. Angiogenesis Inhibition in Breast Cancer. Breast Disease 2019. [DOI: 10.1007/978-3-030-16792-9_34] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Wei J, Luo Y, Fu D. Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2018;11:9049-59. [PMID: 30588017 DOI: 10.2147/OTT.S186816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
67 Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y. A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. Cancer Med 2019;8:383-99. [PMID: 30525293 DOI: 10.1002/cam4.1892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
68 Wu FTH, Xu P, Chow A, Man S, Krüger J, Khan KA, Paez-Ribes M, Pham E, Kerbel RS. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. Br J Cancer 2019;120:196-206. [PMID: 30498230 DOI: 10.1038/s41416-018-0297-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
69 Walsh EM, Shalaby A, O'Loughlin M, Keane N, Webber MJ, Kerin MJ, Keane MM, Glynn SA, Callagy GM. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. Breast Cancer Res Treat. 2019;174:1-13. [PMID: 30488345 DOI: 10.1007/s10549-018-5066-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
70 Appell PG, Rüssel J, Bethge S, Schlitt A. Kardiotoxizität onkologischer Therapien (1): Myokardiale Dysfunktion und Herzinsuffizienz. Deutsches Ärzteblatt Online 2018. [DOI: 10.3238/perskardio.2018.11.02.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. [PMID: 30174444 DOI: 10.2147/OTT.S166151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
72 Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall M, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder S, Nestle FO, Gillett C, Spicer JF, Grigoriadis A, Tutt ANJ, Karagiannis SN. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. Clin Cancer Res 2018;24:5098-111. [PMID: 30068707 DOI: 10.1158/1078-0432.CCR-18-0652] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
73 Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 2018;36:2621-9. [PMID: 30040523 DOI: 10.1200/JCO.2018.79.2028] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
74 Zhou Z, Yao H, Hu H. Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer. Adv Exp Med Biol 2017;1026:171-95. [PMID: 29282684 DOI: 10.1007/978-981-10-6020-5_8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
75 Rodríguez Bautista R, Ortega Gómez A, Hidalgo Miranda A, Zentella Dehesa A, Villarreal-Garza C, Ávila-Moreno F, Arrieta O. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. Clin Epigenetics 2018;10:88. [PMID: 29983835 DOI: 10.1186/s13148-018-0514-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 9.3] [Reference Citation Analysis]
76 Arai RJ, Petry V, Hoff PM, Mano MS. Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy. Biomark Res 2018;6:20. [PMID: 29946467 DOI: 10.1186/s40364-018-0135-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
77 Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 2018;25:S142-50. [PMID: 29910657 DOI: 10.3747/co.25.3954] [Cited by in Crossref: 150] [Cited by in F6Publishing: 158] [Article Influence: 37.5] [Reference Citation Analysis]
78 Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs 2017;77:1313-36. [PMID: 28616845 DOI: 10.1007/s40265-017-0774-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
79 Mountzios G. Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era? Transl Lung Cancer Res 2018;7:S179-82. [PMID: 29782560 DOI: 10.21037/tlcr.2018.03.24] [Reference Citation Analysis]
80 Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Gounaris I, Abraham JE, Hughes-Davies L, McAdam K, Chan S, Ahmad R, Hickish T, Rea D, Caldas C, Bartlett JMS, Cameron DA, Provenzano E, Thomas J, Hayward RL; ARTemis Investigators Group. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. Ann Oncol 2017;28:1817-24. [PMID: 28459938 DOI: 10.1093/annonc/mdx173] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
81 Raghavendra A, Kalita-de Croft P, Vargas AC, Smart CE, Simpson PT, Saunus JM, Lakhani SR. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers. Histopathology 2018;73:68-80. [PMID: 29465777 DOI: 10.1111/his.13498] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
82 Sharma P. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol 2018;19:22. [PMID: 29656345 DOI: 10.1007/s11864-018-0539-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
83 Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncol 2018;4:e175092. [PMID: 29372234 DOI: 10.1001/jamaoncol.2017.5092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
84 Chazova IY, Tyulyandin SA, Vitsenia MV, Panchenko EP, Fedotkina YA, Poltavskaya MG, Gilyarov MY, Martynyuk TV, Ovchinnikov AG, Stenina MB, Trophimova OP, Ageev FT. Clinical manual for diagnosis, prevention and treatment of cardiovascular complications of cancer therapy. Parts VI-VII. System Hyper 2018;15:6-20. [DOI: 10.26442/2075-082x_15.1.6-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
85 Gampenrieder SP, Rinnerthaler G, Hackl H, Pulverer W, Weinhaeusel A, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Risch A, Greil R. DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer. Theranostics 2018;8:2278-88. [PMID: 29721079 DOI: 10.7150/thno.23544] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
86 Orr K, Buckley NE, Haddock P, James C, Parent JL, McQuaid S, Mullan PB. Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs). Oncotarget 2016;7:55458-72. [PMID: 27487152 DOI: 10.18632/oncotarget.10969] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
87 Mendiola M, Martínez-Marin V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto Á, Miguel M, Díaz E, Gámez A, Fresno JÁ, Ramírez de Molina A, Hardisson D, Espinosa E, Redondo A. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. Oncotarget 2016;7:24217-27. [PMID: 26992213 DOI: 10.18632/oncotarget.8128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
88 Poels H, Cuyle P, Van Cutsem E. Should Biological Targeted Agents be Combined with Preoperative Chemoradiation in Rectal Cancer? An Update. Multidisciplinary Management of Rectal Cancer 2018. [DOI: 10.1007/978-3-319-43217-5_36] [Reference Citation Analysis]
89 Makhoul I. Therapeutic Strategies for Breast Cancer. The Breast 2018. [DOI: 10.1016/b978-0-323-35955-9.00024-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
90 Prove A, Teuwen L, Dirix L. Adjuvant Molecular Therapies in Breast Cancer. Breast Cancer Management for Surgeons 2018. [DOI: 10.1007/978-3-319-56673-3_37] [Reference Citation Analysis]
91 Santa-maria CA, Gradishar WJ. Adjuvant and Neoadjuvant Systemic Therapies for Early-Stage Breast Cancer. The Breast 2018. [DOI: 10.1016/b978-0-323-35955-9.00055-6] [Reference Citation Analysis]
92 Ahn KJ, Park J, Choi Y. Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery. Radiat Oncol J 2017;35:332-9. [PMID: 29232804 DOI: 10.3857/roj.2017.00416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
93 Comunanza V, Bussolino F. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front Cell Dev Biol 2017;5:101. [PMID: 29270405 DOI: 10.3389/fcell.2017.00101] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
94 Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2017;18:1610-23. [PMID: 29129443 DOI: 10.1016/S1470-2045(17)30691-5] [Cited by in Crossref: 94] [Cited by in F6Publishing: 108] [Article Influence: 18.8] [Reference Citation Analysis]
95 Gampenrieder SP, Westphal T, Greil R. Antiangiogenic therapy in breast cancer. Memo 2017;10:194-201. [PMID: 29250196 DOI: 10.1007/s12254-017-0362-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
96 Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 2017;18:1595-609. [PMID: 29095114 DOI: 10.2217/pgs-2017-0117] [Cited by in Crossref: 114] [Cited by in F6Publishing: 130] [Article Influence: 22.8] [Reference Citation Analysis]
97 Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer. Oncotarget 2017;8:21806-17. [PMID: 28423521 DOI: 10.18632/oncotarget.15586] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
98 Chagpar AB. On baseball and breast cancer. Am J Surg 2018;215:353-6. [PMID: 28958652 DOI: 10.1016/j.amjsurg.2017.09.004] [Reference Citation Analysis]
99 Gregório AC, Lacerda M, Figueiredo P, Simões S, Dias S, Moreira JN. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathol Oncol Res 2018;24:701-16. [PMID: 28913723 DOI: 10.1007/s12253-017-0307-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
100 Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open 2017;2:e000208. [PMID: 29018573 DOI: 10.1136/esmoopen-2017-000208] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
101 Shao F, Sun H, Deng CX. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. Oncotarget. 2017;8:73329-73344. [PMID: 29069872 DOI: 10.18632/oncotarget.20274] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
102 Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc 2017;6:e006278. [PMID: 28862931 DOI: 10.1161/JAHA.117.006278] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
103 Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget 2017;8:74378-90. [PMID: 29088794 DOI: 10.18632/oncotarget.20102] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
104 Locatelli MA, Curigliano G, Eniu A. Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. Breast Care (Basel) 2017;12:152-8. [PMID: 28785182 DOI: 10.1159/000478087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
105 Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol 2017;9:493-511. [PMID: 28717401 DOI: 10.1177/1758834017711380] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
106 Saiyed MM, Ong PS, Chew L. Perception of oncology practitioners towards off-label use of anticancer medicines in Singapore. J Pharm Health Serv Res 2017;8:91-99. [DOI: 10.1111/jphs.12175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
107 Vetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, Güth U, Rochlitz C, Zanetti-Dällenbach R. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget 2017;8:75617-26. [PMID: 29088896 DOI: 10.18632/oncotarget.18118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
108 Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492-51506. [PMID: 28881662 DOI: 10.18632/oncotarget.18190] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
109 Guimarães E, Machado R, Fonseca MC, França A, Carvalho C, Araújo E Silva AC, Almeida B, Cassini P, Hissa B, Drumond L, Gonçalves C, Fernandes G, De Brot M, Moraes M, Barcelos L, Ortega JM, Oliveira A, Leite MF. Inositol 1, 4, 5-trisphosphate-dependent nuclear calcium signals regulate angiogenesis and cell motility in triple negative breast cancer. PLoS One 2017;12:e0175041. [PMID: 28376104 DOI: 10.1371/journal.pone.0175041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
110 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 320] [Cited by in F6Publishing: 355] [Article Influence: 64.0] [Reference Citation Analysis]
111 Cheuk IW, Shin VY, Kwong A. Detection of Methylated Circulating DNA as Noninvasive Biomarkers for Breast Cancer Diagnosis. J Breast Cancer 2017;20:12-9. [PMID: 28382090 DOI: 10.4048/jbc.2017.20.1.12] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
112 Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017;18:357-70. [PMID: 28163000 DOI: 10.1016/S1470-2045(17)30043-8] [Cited by in Crossref: 174] [Cited by in F6Publishing: 189] [Article Influence: 34.8] [Reference Citation Analysis]
113 Strasser-weippl K. Breast cancer milestones 2007–2016. memo 2017;10:27-32. [DOI: 10.1007/s12254-017-0320-x] [Reference Citation Analysis]
114 Jhan JR, Andrechek ER. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. Oncogene 2017;36:3553-61. [PMID: 28135251 DOI: 10.1038/onc.2016.503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
115 Kirova YM, Fourquet A. Concurrent Use of Radiation Therapy and Targeted Molecules in the Breast Cancer Treatment. Breast Cancer 2017. [DOI: 10.1007/978-3-319-48848-6_54] [Reference Citation Analysis]
116 Celebi JT. Melanoma. Angiogenesis-Based Dermatology 2017. [DOI: 10.1007/978-1-4471-7314-4_5] [Reference Citation Analysis]
117 Paez-ribes M, Munoz R, Guerin E, Man S, Xu P, Ebos J, Lee C, Reynolds A, Shaked Y, Kerbel RS. Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics. Molecular and Translational Medicine 2017. [DOI: 10.1007/978-3-319-57424-0_12] [Reference Citation Analysis]
118 Furlanetto J, von Minckwitz G. Primary Systemic Therapies: Guidelines. Breast Cancer 2017. [DOI: 10.1007/978-3-319-48848-6_43] [Reference Citation Analysis]
119 Maas AHEM. Cardiotoxicity During and After Breast Cancer Treatment. Manual of Gynecardiology 2017. [DOI: 10.1007/978-3-319-54960-6_7] [Reference Citation Analysis]
120 Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, Foroud T, Sledge GW Jr. Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clin Cancer Res. 2017;23:43-51. [PMID: 27993963 DOI: 10.1158/1078-0432.ccr-16-0908] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
121 Bear HD, Tang G, Rastogi P, Geyer CE, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol. 2017;24:1853-1860. [PMID: 27864694 DOI: 10.1245/s10434-016-5662-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
122 Wu FT, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, Kerbel RS. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Sci Rep 2016;6:36694. [PMID: 27841282 DOI: 10.1038/srep36694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
123 Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget 2015;6:42396-410. [PMID: 26623560 DOI: 10.18632/oncotarget.6377] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
124 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
125 Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A, D'Aiuto M. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 2015;6:26560-74. [PMID: 26387133 DOI: 10.18632/oncotarget.5306] [Cited by in Crossref: 102] [Cited by in F6Publishing: 113] [Article Influence: 17.0] [Reference Citation Analysis]
126 Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18. [PMID: 27009393 DOI: 10.1038/nrc.2016.25] [Cited by in Crossref: 837] [Cited by in F6Publishing: 886] [Article Influence: 139.5] [Reference Citation Analysis]
127 Gonçalves A. [Not Available]. Bull Cancer 2016;103:S76-89. [PMID: 27494978 DOI: 10.1016/S0007-4551(16)30149-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
128 Carey LA. CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. Clin Cancer Res 2015;21:4027-9. [PMID: 26374072 DOI: 10.1158/1078-0432.CCR-14-3124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
129 Sharma P. Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist 2016;21:1050-62. [PMID: 27401886 DOI: 10.1634/theoncologist.2016-0067] [Cited by in Crossref: 131] [Cited by in F6Publishing: 148] [Article Influence: 21.8] [Reference Citation Analysis]
130 Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 2016;158:485-95. [PMID: 27393622 DOI: 10.1007/s10549-016-3889-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 10.0] [Reference Citation Analysis]
131 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
132 Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 2016;34:3400-8. [PMID: 27325862 DOI: 10.1200/JCO.2015.65.6595] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
133 Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) 2016;8:93-107. [PMID: 27284266 DOI: 10.2147/BCTT.S69488] [Cited by in Crossref: 63] [Cited by in F6Publishing: 150] [Article Influence: 10.5] [Reference Citation Analysis]
134 Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 2016;34:2602-9. [PMID: 27138575 DOI: 10.1200/JCO.2015.66.1595] [Cited by in Crossref: 74] [Cited by in F6Publishing: 81] [Article Influence: 12.3] [Reference Citation Analysis]
135 Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol 2016;13:611-26. [PMID: 27118493 DOI: 10.1038/nrclinonc.2016.57] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 14.3] [Reference Citation Analysis]
136 Chism DD, Rathmell WK. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Nat Rev Nephrol 2016;12:317-8. [PMID: 27108841 DOI: 10.1038/nrneph.2016.58] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
137 Subramaniam S, Bhoo-Pathy N, Taib NA, Tan GH, See MH, Jamaris S, Ho GF, Looi LM, Yip CH. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country. World J Surg 2015;39:2450-8. [PMID: 26138872 DOI: 10.1007/s00268-015-3133-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
138 Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 2015;6:12890-908. [PMID: 25973541 DOI: 10.18632/oncotarget.3849] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 12.2] [Reference Citation Analysis]
139 De Mattos-Arruda L, Shen R, Reis-Filho JS, Cortés J. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol 2016;13:566-79. [PMID: 27000962 DOI: 10.1038/nrclinonc.2016.35] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
140 Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008-2016. [PMID: 26969090 DOI: 10.1016/s0140-6736(16)00559-6] [Cited by in Crossref: 385] [Cited by in F6Publishing: 426] [Article Influence: 64.2] [Reference Citation Analysis]
141 Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer 2016;16:143. [PMID: 26908167 DOI: 10.1186/s12885-016-2198-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
142 Eeden RV, Rapoport BL. Triple-negative breast cancer – the past, present and future: recent and emerging trends in immunotherapy. Breast Cancer Management 2016;5:1-5. [DOI: 10.2217/bmt-2016-0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
143 Friend S, Royce M. The Changing Landscape of Breast Cancer: How Biology Drives Therapy. Medicines (Basel) 2016;3:E2. [PMID: 28930112 DOI: 10.3390/medicines3010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
144 Kelley RK. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncol 2015;16:1279-81. [PMID: 26433814 DOI: 10.1016/S1470-2045(15)00296-X] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
145 Rabaglio M, Castiglione M. Breast Cancer in Younger Women. Management of Breast Diseases 2016. [DOI: 10.1007/978-3-319-46356-8_29] [Reference Citation Analysis]
146 Marmé F. Systemic Therapy. Management of Breast Diseases 2016. [DOI: 10.1007/978-3-319-46356-8_20] [Reference Citation Analysis]
147 Liedtke C, Rody A. Neoadjuvant Systemic Treatment (NST). Management of Breast Diseases 2016. [DOI: 10.1007/978-3-319-46356-8_23] [Reference Citation Analysis]
148 Kilic L, Aydiner A. Adjuvant Systemic Chemotherapy for HER2-Negative Disease. Breast Disease 2016. [DOI: 10.1007/978-3-319-26012-9_8] [Reference Citation Analysis]
149 Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 2015;16:575. [PMID: 26673577 DOI: 10.1186/s13063-015-1101-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
150 Mross K. VEGFR2-Hemmer bei metastasiertem Brustkrebs ohne Zusatznutzen. Info Onkol 2015;18:38-40. [DOI: 10.1007/s15004-015-0942-2] [Reference Citation Analysis]
151 Earl H, Provenzano E, Abraham J, Dunn J, Vallier AL, Gounaris I, Hiller L. Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean? BMC Med 2015;13:234. [PMID: 26391216 DOI: 10.1186/s12916-015-0472-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
152 Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother 2015;16:983-98. [PMID: 25881743 DOI: 10.1517/14656566.2015.1032246] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 8.4] [Reference Citation Analysis]
153 Raymaekers K, Stegen S, van Gastel N, Carmeliet G. The vasculature: a vessel for bone metastasis. Bonekey Rep 2015;4:742. [PMID: 27217954 DOI: 10.1038/bonekey.2015.111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
154 Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10:e0136324. [PMID: 26331473 DOI: 10.1371/journal.pone.0136324] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
155 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 117] [Cited by in F6Publishing: 124] [Article Influence: 16.7] [Reference Citation Analysis]
156 Kuritzky B, Sikov WM. How high a bar to change neoadjuvant therapy for triple-negative breast cancer? J Comp Eff Res 2015;4:293-6. [PMID: 26274790 DOI: 10.2217/cer.15.29] [Reference Citation Analysis]
157 Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 2015;16:1037-48. [PMID: 26272770 DOI: 10.1016/S1470-2045(15)00041-8] [Cited by in Crossref: 113] [Cited by in F6Publishing: 122] [Article Influence: 16.1] [Reference Citation Analysis]
158 Mustacchi G, De Laurentiis M. The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther 2015;9:4303-18. [PMID: 26273192 DOI: 10.2147/DDDT.S86105] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
159 Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med 2014;6:1561-76. [PMID: 25361689 DOI: 10.15252/emmm.201403989] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
160 Tudoran O, Soritau O, Balacescu L, Visan S, Barbos O, Cojocneanu-Petric R, Balacescu O, Berindan-Neagoe I. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells. Mol Cell Biochem 2015;409:163-76. [PMID: 26187676 DOI: 10.1007/s11010-015-2522-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
161 Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy? Geburtshilfe Frauenheilkd 2015;75:574-83. [PMID: 26166838 DOI: 10.1055/s-0035-1546150] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
162 Marmé F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) 2015;10:159-66. [PMID: 26557820 DOI: 10.1159/000433622] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
163 Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, Padera TP. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. J Natl Cancer Inst 2015;107:djv155. [PMID: 26063793 DOI: 10.1093/jnci/djv155] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
164 Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Soy and breast cancer: focus on angiogenesis. Int J Mol Sci 2015;16:11728-49. [PMID: 26006245 DOI: 10.3390/ijms160511728] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 13.6] [Reference Citation Analysis]
165 Wang ZP, Zhang HF, Zhang F, Hu BL, Wei HT, Guo YY. Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis. Eur J Clin Pharmacol 2015;71:517-24. [PMID: 25845654 DOI: 10.1007/s00228-015-1818-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Gandhi S, Fletcher GG, Eisen A, Mates M, Freedman OC, Dent SF, Trudeau ME. Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 2015;22:S82-94. [PMID: 25848343 DOI: 10.3747/co.22.2321] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
167 Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J Cancer. 2015;112:1199-1205. [PMID: 25756398 DOI: 10.1038/bjc.2015.73] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
168 Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol 2015;22:1408-15. [PMID: 25727557 DOI: 10.1245/s10434-015-4405-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
169 Untch M, Thomssen C. Adjuvante und neoadjuvante Chemotherapie des Mammakarzinoms. Onkologe 2015;21:231-238. [DOI: 10.1007/s00761-014-2839-3] [Reference Citation Analysis]
170 Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Bollet M, Vago NA, Dendale R, Campana F, Fourquet A, Kirova YM. Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer. Br J Radiol 2015;88:20140800. [PMID: 25645108 DOI: 10.1259/bjr.20140800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
171 Zhang L, Fang C, Xu X, Li A, Cai Q, Long X. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Res Int 2015;2015:357485. [PMID: 25695063 DOI: 10.1155/2015/357485] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
172 Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L, Tomao S. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther 2015;8:177-93. [PMID: 25653541 DOI: 10.2147/OTT.S67673] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 12.7] [Reference Citation Analysis]
173 Selvi R. Targeted Therapies. Breast Diseases 2015. [DOI: 10.1007/978-81-322-2077-0_43] [Reference Citation Analysis]
174 Guo S, Wong S. Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol 2014;4:346. [PMID: 25538891 DOI: 10.3389/fonc.2014.00346] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
175 Bachmann C, Schmidt S, Staebler A, Fehm T, Fend F, Schittenhelm J, Wallwiener D, Grischke E. CNS metastases in breast cancer patients: prognostic implications of tumor subtype. Med Oncol 2015;32:400. [PMID: 25433950 DOI: 10.1007/s12032-014-0400-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
176 Coussy F, Teixeira L, Giacchetti S, Cuvier C, Hocini H, Espié M. Nouveautés sur les thérapies ciblées dans le cancer du sein. Gynécologie Obstétrique & Fertilité 2014;42:787-794. [DOI: 10.1016/j.gyobfe.2014.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
177 Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 2015;33:177-86. [PMID: 25323060 DOI: 10.1007/s10637-014-0173-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
178 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 261] [Cited by in F6Publishing: 275] [Article Influence: 32.6] [Reference Citation Analysis]
179 Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 11.0] [Reference Citation Analysis]
180 Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, Liu P, Zhang J. The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 2014;6:1329-35. [PMID: 25276378 DOI: 10.3978/j.issn.2072-1439.2014.08.13] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
181 Nag S, Mane A, Gupta S. Emerging Prognostic and Predictive Biomarkers for Triple Negative Breast Cancer. Curr Breast Cancer Rep 2014;6:275-82. [DOI: 10.1007/s12609-014-0165-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 2014;13:3175-84. [PMID: 25253784 DOI: 10.1158/1535-7163.MCT-14-0358] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
183 Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS One 2014;9:e108405. [PMID: 25247558 DOI: 10.1371/journal.pone.0108405] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
184 Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthélémy P. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Target Oncol 2015;10:189-98. [PMID: 25185646 DOI: 10.1007/s11523-014-0334-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
185 Loibl S, Rokitta D, Conrad B, Harbeck N, Wüllner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H. Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel). 2014;9:169-174. [PMID: 25177258 DOI: 10.1159/000363430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
186 Stickeler E, Fehm T. Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years? Breast Care (Basel) 2014;9:161-7. [PMID: 25177257 DOI: 10.1159/000365129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
187 Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P, Lim B. Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Res 2014;3:198. [PMID: 25400908 DOI: 10.12688/f1000research.4340.1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
188 Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer 2014;111:1241-8. [PMID: 25117820 DOI: 10.1038/bjc.2014.430] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
189 Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13-21. [PMID: 25092775 DOI: 10.1200/jco.2014.57.0572] [Cited by in Crossref: 580] [Cited by in F6Publishing: 636] [Article Influence: 72.5] [Reference Citation Analysis]
190 Shinoda C, Mori R, Nagao Y. Two cases of mastectomy after Paclitaxel + bevacizumab therapy for locally advanced breast cancer. Case Rep Oncol 2014;7:323-9. [PMID: 24932175 DOI: 10.1159/000363098] [Reference Citation Analysis]
191 Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs 2014;32:1285-94. [PMID: 24894652 DOI: 10.1007/s10637-014-0122-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
192 Arrondeau J, Giacchetti S, Colle E, Chibaudel B. Revue de Presse de L’Aerio / Aerio Press Review. Oncologie 2014;16:263-266. [DOI: 10.1007/s10269-014-2398-7] [Reference Citation Analysis]
193 Jacot W. 36th San Antonio Breast Cancer Symposium: focus on clinical trial results. Future Oncol 2014;10:511-3. [PMID: 24754580 DOI: 10.2217/fon.14.11] [Reference Citation Analysis]
194 Shakir AR. Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer. Case Rep Oncol 2014;7:252-9. [PMID: 24847251 DOI: 10.1159/000362443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
195 Guerrero Á, Gavilá J, Climent MA, Guillem V, Ruíz A. 36th annual San Antonio Breast Cancer Symposium. Resumen de lo más destacado. Revista de Senología y Patología Mamaria 2014;27:87-93. [DOI: 10.1016/j.senol.2014.02.001] [Reference Citation Analysis]
196 Welsh SJ, Janowitz T, Corrie P. Mechanism of action of approved antiangiogenesis agents: overview for clinicians. Antiangiogenesis in Cancer Therapy 2014. [DOI: 10.2217/ebo.13.732] [Reference Citation Analysis]
197 Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, Lee S, Jung KC, Lee YS, Jeong JM, Lee DS, Chung JK, Moon WK. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2014;41:1534-43. [PMID: 24652232 DOI: 10.1007/s00259-014-2744-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
198 Singel SM, Batten K, Cornelius C, Jia G, Fasciani G, Barron SL, Wright WE, Shay JW. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast Cancer Res 2014;16:R28. [PMID: 24642040 DOI: 10.1186/bcr3629] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
199 Leiter A, Galsky MD. Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better? Eur Urol 2014;66:881-3. [PMID: 24631407 DOI: 10.1016/j.eururo.2014.02.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
200 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
201 Harbeck N, Sotlar K. Tripelnegatives Mammakarzinom. best practice onkologie 2014;9:6-10. [DOI: 10.1007/s11654-013-0111-8] [Reference Citation Analysis]
202 Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142-150. [PMID: 24114677 DOI: 10.1002/path.4280] [Cited by in Crossref: 263] [Cited by in F6Publishing: 282] [Article Influence: 32.9] [Reference Citation Analysis]
203 Irshad S, Tutt A, Ellis P. Antiangiogenic therapy: patient selection and clinical outcomes. Personalized Management of Breast Cancer 2014. [DOI: 10.2217/ebo.12.431] [Reference Citation Analysis]
204 Fakhrejahani E, Toi M. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Jpn J Clin Oncol 2014;44:197-207. [PMID: 24474817 DOI: 10.1093/jjco/hyt201] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
205 Hagiwara C, Kitagawa D, Horiguchi S, Yamashita T, Kuroi K. Two Cases of Matrix-producing Carcinoma of the Breast Showing Different Clinical Courses after Initial Therapy. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2014;75:2130-2135. [DOI: 10.3919/jjsa.75.2130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
206 Hutchinson L. Breast cancer: BEATRICE bevacizumab trial--every cloud has a silver lining. Nat Rev Clin Oncol 2013;10:548. [PMID: 23982522 DOI: 10.1038/nrclinonc.2013.161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]